Gemini Bioproducts, a supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, a New York-based healthcare private equity firm, has formed an exclusive distribution agreement for Canada with Toronto-based FroggaBio. Starting immediately, customers in Canada will be able to purchase Gemini’s current and future products directly from FroggaBio. Gemini expects the agreement to result in significant growth, after previously serving the Canadian market from its U.S...